We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Grants Fast Track Designation to Aridis’ Acute Pneumonia Therapy
FDA Grants Fast Track Designation to Aridis’ Acute Pneumonia Therapy
Aridis Pharmaceuticals has received FDA fast track designation for its AR-301, a monoclonal antibody that is under development to treat acute pneumonia caused by certain bacteria, including multidrug-resistant MRSA strains.